Roger D. Tung
2017
In 2017, Roger D. Tung earned a total compensation of $3.4M as President and Chief Executive Officer at Concert Pharmaceuticals, a 30% increase compared to previous year.
Compensation breakdown
Non-Equity Incentive Plan | $297,506 |
---|---|
Option Awards | $1,496,440 |
Salary | $517,402 |
Stock Awards | $1,109,600 |
Other | $9,906 |
Total | $3,430,854 |
Tung received $1.5M in option awards, accounting for 44% of the total pay in 2017.
Tung also received $297.5K in non-equity incentive plan, $517.4K in salary, $1.1M in stock awards and $9.9K in other compensation.
Rankings
In 2017, Roger D. Tung's compensation ranked 3,079th out of 14,666 executives tracked by ExecPay. In other words, Tung earned more than 79.0% of executives.
Classification | Ranking | Percentile |
---|---|---|
All | 3,079 out of 14,666 | 79th |
Division Manufacturing | 1,061 out of 5,772 | 82nd |
Major group Chemicals And Allied Products | 286 out of 2,075 | 86th |
Industry group Drugs | 217 out of 1,731 | 88th |
Industry Pharmaceutical Preparations | 172 out of 1,333 | 87th |
Source: SEC filing on May 3, 2018.
Tung's colleagues
We found two more compensation records of executives who worked with Roger D. Tung at Concert Pharmaceuticals in 2017.
News
Concert Pharmaceuticals CEO Roger Tung's 2021 pay rises 17% to $3.5M
April 26, 2022
Concert Pharmaceuticals CEO Roger Tung's 2020 pay rises 9% to $3M
April 27, 2021
Concert Pharmaceuticals CEO Roger Tung's 2019 pay falls 40% to $2.8M
April 28, 2020
Concert Pharmaceuticals CEO Roger Tung's 2018 pay jumps 34% to $4.6M
April 29, 2019